Quick Picks - On the same day that the company released exciting data from a pre-clinical stemcell experiment in rats – sending shares up more than 90% from … Continue Reading
Read NowQuick Picks - Pluristem Therapeutics (NASDAQ:PSTI) gapped down 15% Thursday morning after an announcement that the company will be raising capital through the sale of $32M in common … Continue Reading
Read NowQuick Picks - After the markets’ close Tuesday, Santarus Inc. (NASDAQ:SNTS) reported top-line data from a phase III trial of rifamycin SV MMX, sending shares up 6% in … Continue Reading
Read NowQuick Picks - On Wednesday morning, Opexa Therapeutics (NASDAQ:OPXA) announced the initiation of a Phase IIb trial, called Alibi-T, for Tcelna, the company’s T-cell therapy for multiple sclerosis. … Continue Reading
Read NowQuick Picks - After a run-up to $1.44 last week, Chelsea Therapeutics (NASDAQ:CHTP) has been giving up gains as momentum ebbed and the company released no major updates … Continue Reading
Read NowLong Ideas - The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will meet this Thursday to discuss the NDA for Cornerstone Therapeutics’ (NASDAQ:CRTX) lixivaptan for the treatment … Continue Reading
Read NowMost Popular - Cell Therapeutics (NASDAQ:CTIC) closed 10% higher on Monday in anticipation of positive trial data from management at the Rodman & Renshaw Conference in NYC. The … Continue Reading
Read Now